ArticleNutrition & metabolism2026
Assessment of insulin resistance indexes with longitudinal trajectories of cardiometabolic multimorbidity: insights from the UK Biobank.
Article in Nutrition & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundInsulin resistance is a key pathophysiological mechanism potentially linking cardiometabolic diseases, yet the comparative performance of various surrogate indexes in predicting disease trajectories remains unclear. Therefore, this study aimed to evaluate the associations between insulin resistance indexes and cardiometabolic disease trajectories, and to identify the most suitable index for clinical risk assessment.
methodsThis prospective cohort study included 357,759 participants free of cardiometabolic diseases at baseline from the UK Biobank. We assessed seven insulin resistance indexes (estimated glucose disposal rate [eGDR], triglyceride-glucose index [TyG], triglyceride-glucose-waist circumference index [TyG-WC], triglyceride-glucose-body mass index [TyG-BMI], triglyceride-glucose-waist-to-height ratio [TyG-WHtR], triglyceride to high-density lipoprotein cholesterol ratio [TG/HDL-C], and metabolic score for insulin resistance [METS-IR]) and applied multi-state models to analyze disease trajectories from baseline to first cardiometabolic disease (FCMD), cardiometabolic multimorbidity (CMM) and death.
resultsDuring follow-up, 47,125 participants developed FCMD, 5,326 progressed to CMM, and 26,074 died. Among all indexes, eGDR exhibited the highest predictive value for both FCMD (AUC = 0.690) and CMM (AUC = 0.754), followed by TyG-WHtR and TyG-WC. Higher eGDR was associated with lower risks of transitioning from baseline to FCMD (HR = 0.63, 95%CI:0.62–0.64) and from FCMD to CMM (HR = 0.78, 95%CI:0.74–0.81). Conversely, higher TyG-WC and TyG-WHtR increased risks of transitions from baseline to FCMD (HR = 1.52, 95%CI:1.48–1.56; HR = 1.55, 95%CI:1.52–1.59) and from FCMD to CMM (HR = 1.21, 95%CI:1.13–1.30; HR = 1.24, 95%CI:1.16–1.32). Disease-specific analysis revealed insulin resistance indexes exhibited strongest effects on type 2 diabetes-related transitions (eGDR: HR = 0.49, 95%CI:0.48–0.50; TyG-WC: HR = 2.37, 95%CI:2.28–2.45). These associations remained consistent across major demographic subgroups.
conclusionsInsulin resistance indexes, particularly eGDR, effectively predict cardiometabolic disease trajectories. These findings underscore insulin resistance’s role in disease progression and suggest eGDR as a valuable clinical risk stratification tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.